期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Overview of the microbiota in the gut-liver axis in viral B and C hepatitis 被引量:2
1
作者 maria adriana neag Andrei Otto Mitre +1 位作者 Adrian Catinean Anca Dana Buzoianu 《World Journal of Gastroenterology》 SCIE CAS 2021年第43期7446-7461,共16页
Viral B and C hepatitis are a major current health issue,both diseases having a chronic damaging effect on the liver and its functions.Chronic liver disease can lead to even more severe and life-threatening conditions... Viral B and C hepatitis are a major current health issue,both diseases having a chronic damaging effect on the liver and its functions.Chronic liver disease can lead to even more severe and life-threatening conditions,such as liver cirrhosis and hepatocellular carcinoma.Recent years have uncovered an important interplay between the liver and the gut microbiome:the gut-liver axis.Hepatitis B and C infections often cause alterations in the gut microbiota by lowering the levels of‘protective’gut microorganisms and,by doing so,hinder the microbiota ability to boost the immune response.Treatments aimed at restoring the gut microbiota balance may provide a valuable addition to current practice therapies and may help limit the chronic changes observed in the liver of hepatitis B and C patients.This review aims to summarize the current knowledge on the anatofunctional axis between the gut and liver and to highlight the influence that hepatitis B and C viruses have on the microbiota balance,as well as the influence of treatments aimed at restoring the gut microbiota on infected livers and disease progression. 展开更多
关键词 Viral B hepatitis Viral C hepatitis Gut-liver axis IMMUNOMODULATION LIPOPOLYSACCHARIDES Short-chain fatty acids
下载PDF
Gastrointestinal microbiota:A predictor of COVID-19 severity?
2
作者 maria adriana neag Damiana-maria Vulturar +3 位作者 Diana Gherman Codrin-Constantin Burlacu Doina Adina Todea Anca Dana Buzoianu 《World Journal of Gastroenterology》 SCIE CAS 2022年第45期6328-6344,共17页
Coronavirus disease 2019(COVID-19),caused by a severe acute respiratory syndrome coronavirus 2 infection,has raised serious concerns worldwide over the past 3 years.The severity and clinical course of COVID-19 depends... Coronavirus disease 2019(COVID-19),caused by a severe acute respiratory syndrome coronavirus 2 infection,has raised serious concerns worldwide over the past 3 years.The severity and clinical course of COVID-19 depends on many factors(e.g.,associated comorbidities,age,etc)and may have various clinical and imaging findings,which raises management concerns.Gut microbiota composition is known to influence respiratory disease,and respiratory viral infection can also influence gut microbiota.Gut and lung microbiota and their relationship(gut-lung axis)can act as modulators of inflammation.Modulating the intestinal microbiota,by improving its composition and diversity through nutraceutical agents,can have a positive impact in the prophylaxis/treatment of COVID-19. 展开更多
关键词 Gut microbiota COVID-19 Prognostic biomarkers Gut-lung axis PROBIOTICS NUTRACEUTICALS
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部